EPZM - エピザイム (Epizyme Inc.) エピザイム

 EPZMのチャート


 EPZMの企業情報

symbol EPZM
会社名 Epizyme Inc. (エピザイム)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エピザイム(Epizyme Inc.)は臨床段階のバイオ医薬品会社である。同社はがん患者向けエピジェネティック治療法の発見・開発・商品化する計画を行う。同社は、がん患者向け新規エピジェネティック治療法の発見・開発に従事する。同社はヒストンメチルトランスフェラーゼ(HMT)として知られる各種酵素小分子阻害剤を開発する。同社は他のクロマチン修飾タンパク質(CMP)の小分子阻害剤を開発する。同社のリード製品候補であるタゼメトスタットは、各種がんにおいて役割を果たす酵素であるゼスト相同体2(EZH2)ヒストンメチルトランスフェラーゼ(HMT)のエンハンサーの選択的阻害剤である。同社は再発性または難治性の非ホジキンリンパ腫(NHL)を有する成人第II相試験及び分子標的腫瘍を有する小児の第I相試験でタゼメトスタットを評価する。同社は日本以外のタゼメトスタットに対する世界的開発・商業化権利を有する。   エピザイムは、米国のバイオ医薬品企業。遺伝によるがん患者向けに個別の治療薬の開発、商品化を行う。ヒストンメチルトランスフェラ―ゼとして知られる酵素の阻害剤作成用に独自の製品プラットフォ―ムを開発。遺伝子変異を持つ急性白血病や、遺伝による非ホジキンリンパ腫および固形腫瘍の治療薬の開発を手掛ける。本社はマサチュ―セッツ州ケンブリッジ。  Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
本社所在地 400 Technology Square Cambridge MA 02139 USA
代表者氏名 David M. Mott デビッド・モット
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-229-5872
設立年月日 39387
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 131人
url www.epizyme.com
nasdaq_url https://www.nasdaq.com/symbol/epzm
adr_tso
EBITDA EBITDA(百万ドル) -139.26100
終値(lastsale) 9.23
時価総額(marketcap) 641865774.42
時価総額 時価総額(百万ドル) 737.47240
売上高 売上高(百万ドル) 12.00000
企業価値(EV) 企業価値(EV)(百万ドル) 521.91640
当期純利益 当期純利益(百万ドル) -136.95600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Epizyme Inc revenues increased 20% to $12M. Net loss increased 4% to $63.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 11% to $54.6M (expense) Stock-based Compensation in SGA increase of 38% to $4M (expense) Other income decrease of 50% to $7K (income).

 EPZMのテクニカル分析


 EPZMのニュース

   Epizyme gains as peer Constellation attracts sizable premium from MorphoSys  2021/06/02 16:48:57 Seeking Alpha
   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study  2021/03/05 13:15:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.
   Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call  2021/03/02 17:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s strategic vision and focus on oncology treatment with the Company’s epigenetic pipeline. A link to the presentation and slideshow can be found here. “The recent accelerated approvals of TAZVERIK in Epithelioid Sarcoma and Relapsed / Refractory Follicular Lymphoma are, of c
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Barclays Stick to Their Buy Rating for Epizyme By Investing.com  2021/02/25 01:15:23 Investing.com
Barclays Stick to Their Buy Rating for Epizyme
   Global Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2020 Featuring Takeda Oncology, Epizyme, Vyriad, Novartis, DNAtrix, Pfizer, Oncoceutics & Istari Oncology - ResearchAndMarkets.com  2021/02/05 12:49:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight - 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2020," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape
   Epizyme to Participate in Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference
   Epizyme Wall street estimates Earnings report Stock market Insights & financial analysis  2020/11/06 15:20:00 Stock Market Daily
Epizyme announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Epizyme Reports Business Progress and Third Quarter 2020 Financial Results  2020/11/06 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported third quarter 2020 financial results. “2020 has been a year of big milestones for Epizyme, and we are executing our TAZVERIK® launches well, given the unprecedented challenges presented by the COVID-19 pandemic on FL patients’ access to their physicians and on ac
   Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives  2020/11/06 11:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million. Epizyme and Pharmakon Advisors originally executed their agreement in November 2019, in conjunc

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エピザイム EPZM Epizyme Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)